SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is gaining attention for its potential in the crypto payments infrastructure, particularly due to its compliance-first design and high transaction throughput, addressing a key need for institutional adoption. The community is focused on Keeta's ability to complement existing L1 networks with its settlement and cross-chain routing capabilities, emphasizing its real-world applications through partnerships with companies like Stripe. Participants view Keeta as an infrastructure play poised for growth, potentially undervalued compared to its future capabilities in the financial sector.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining attention as a culture coin on the Solana network, drawing comparisons to Bitcoin. The community emphasizes its focus on creativity, positivity, and innovation within the cannabis culture, highlighting the long-term vision and organic growth.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending due to speculation surrounding potential federal policy changes on cannabis, with rumors of Trump considering reclassification. The community is actively discussing the possibility of a short squeeze and potential price targets, while also weighing the impact of the company's recent reverse stock split. Sector peers are also seeing increased interest amid the broader conversation around cannabis reform.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid discussions about its potential integration with XRP and general market optimism, though some community members express concerns about network stability and past security breaches.  Community discussions are centered around staking opportunities and various meme coins built on the Solana blockchain, like Weedcoin. Speculation around potential partnerships and upcoming announcements also seem to be driving interest in SOL.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom's earnings and AI chip orders are driving intense discussion, with the community dissecting whether recent price action signals a buying opportunity or profit-taking. Talk centers on analysts' target prices and the implications of Broadcom's AI partnerships, particularly in light of broader market trends. Some traders are pointing to potential gross margin compression as reasons to be cautious.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending following a Q3 earnings beat, increased full-year guidance, and news of a CEO succession plan along with a substantial buyback authorization. The community is discussing the company's strong international performance, potential analyst upgrades, and whether this signals a true turnaround for the athleisure brand.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is gaining significant traction, with community members highlighting its strong momentum and potential as the next big ERC-20 narrative on Ethereum; some are pointing to a 'prophecy' involving $YEE alongside $DOGE and $PEPE. The community buzz suggests growing confidence and accumulation, positioning $YEE for a potential breakout.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending as traders discuss its potential in the space/defense sector following recent announcements, with some eyeing a run to higher price levels. Community members are pointing to its low valuation relative to competitors like Kalshi and Polymarket, suggesting significant upside. Bullish sentiment is fueled by its recent CFTC designated contract market license allowing regulated prediction markets.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

VELO is trending due to a potential connection with SpaceX and growing interest in defense contracts, sparking excitement among investors. The community is discussing the company's unique technology and its potential for high-value, complex parts manufacturing. Recent partnerships and certifications are also fueling speculation about upcoming catalysts.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions around Trump's AI policies and actions like seizing an oil tanker, sparking debates about government overreach and potential benefits. The community is actively questioning the stock's valuation relative to its financials and the implications of political affiliations on investment decisions. Some investors express strong support, while others voice concerns about the company's long-term viability and leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Cathie Wood Loves This Under-the-Radar AI Stock. Is It Time for You to Buy Now?

The popular investor poured $366.2 million in the company’s shares to carry out her latest purchase.

Shares of Tempus AI, Inc. were volatile Tuesday, surging to highs last seen in mid-November before paring gains to trade slightly higher.Trading volume was nearly double the daily average as the healthcare tech firm confirmed it will report fourth-quarter and full-year 2024 earnings on Feb. 24, with a conference call at 4:30 p.m. ET.Wall Street expects the company to report an adjusted loss of $0.16 per share on revenue of $203.12 million.Retail sentiment on Stocktwits remained ‘bullish,’ though the score read slightly lower than last week following insider selling.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TEM_sentiment_and_message_volume_Feb_11_564e2ba31d.png" alt="TEM sentiment and message volume Feb 11.png" width="1318" height="324"><figcaption>TEM sentiment and message volume Feb 11 as of 11:45 am ET | source: Stocktwits</figcaption></figure>CEO and Chairman Eric Lefkofsky recently sold nearly 240,000 shares between Feb. 5-7, netting over $16.2 million, while CFO Jim Rogers sold 8,712 shares for $588,669, as per SEC filings.Stocktwits users had mixed reactions. One trader noted the stock “gave back most of the pump,” suggesting weak holding interest amid short pressure.&nbsp;Another pointed to a bullish technical setup, predicting a move toward $80.<stembedurl>https://stocktwits.com/phijammaslamma/message/603757859</stembedurl><stembedurl>https://stocktwits.com/CoBear/message/603746559</stembedurl>Tempus AI has gained a lot of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tem-stock-heads-for-best-rally-in-5-months/chb9WlYR8z">attention</a> since launching an AI-enabled personal health app last month.But it also made headlines after former House Speaker Nancy Pelosi purchased 50 call options in the stock, a trade closely watched by retail investors.Last week, the company announced the completion of its $600 million acquisition of Ambry Genetics.&nbsp;TD Cowen reportedly believes the acquisition strengthens Tempus with a $300-million profitable lab, enhances product offerings, and accelerates its path to positive free cash flow.The research firm, however, thinks Ambry’s slower growth is a concern.Tempus AI stock has surged over 70% since its June 2024 IPO, with its Stocktwits following up nearly 700% in three months.&nbsp;Short interest has also climbed from 3.9% at the start of 2025 to 7.3% by the end of January, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. 

Tempus AI Stock Swings Wildly As Earnings Near, Retail’s Cautiously Optimistic After Insider Sales 

The company has gained a lot of attention since launching an AI-enabled personal health app last month.

Equity

Cathie Wood Just Doubled Down on This AI Stock. Should You?

The stock is one of the renowned investor’s top holdings.

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal Weight’ from ‘Overweight,’ slashing its price target from $56 to $11.&nbsp;The downgrade and what the brokerage says is a broader lack of catalysts for the year dented retail sentiment, with conversations on Stocktwits turning more skeptical.Morgan Stanley cited a “more measured launch” for nexiguran ziclumeran, Intellia’s lead therapy for transthyretin amyloidosis, a rare and progressive heart disorder.&nbsp;The brokerage also pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.The analyst noted growing competition from non-gene-editing therapies, which could challenge Intellia’s position as a leader in “in vivo” CRISPR editing.&nbsp;Intellia’s approach reportedly delivers CRISPR components directly into the body to modify DNA, bypassing the need to engineer treatments from a patient’s cells.Earlier this month, Intellia announced a 27% workforce reduction and plans to halt&nbsp;the development of NTLA-3001 and some early-stage research programs.The company expects to incur $8 million in restructuring charges in the first quarter but believes the changes, combined with its cash balance of $862 million at the end of the fourth quarter, will extend its cash runway into the first half of 2027.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NTLA_sentiment_and_message_volume_Jan_27_414be9f90a.png" alt="NTLA sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>NTLA sentiment and message volume Jan 27 as of 11:40 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned more ‘bearish’ following the downgrade.&nbsp;<stembedurl>https://stocktwits.com/KimAntony/message/601612137</stembedurl><stembedurl>https://stocktwits.com/CharlesEscobar/message/601578564</stembedurl><a href="https://stocktwits.com/symbol/NTLA">Intellia’s stock</a> has a high short interest of 21.3% and has lost nearly 60% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

Shares of Tempus AI climbed more than 5% on Thursday afternoon, poised for their longest winning streak since August 2024.&nbsp;The healthcare technology company has surged from $35 to $53 in just three days, drawing significant retail attention.On Tuesday, Tempus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tempus-ai-stock-surges-on-ai-enabled-healthcare-app-launch-pelosi-buy/chbdxNURFV">introduced</a> an artificial intelligence-powered healthcare concierge app for patients, sparking optimism about its potential in the growing AI healthcare space.A routine stock trading disclosure revealed former House Speaker Nancy Pelosi purchased 50 call options on Tempus, expiring in January 2026 with a $20 strike price. This added to the speculative excitement surrounding the stock.President Donald Trump’s announcement of “Stargate,” a joint venture with OpenAI, Oracle, and SoftBank to invest billions in domestic AI development, further fueled investor enthusiasm for AI-related stocks like Tempus.While Tempus managed to see a 186% growth in retail followers on Stocktwits since Tuesday, sentiment shifted from ‘extremely bullish’ to ‘bearish’ by Thursday afternoon.&nbsp;The platform saw a spike in pessimistic messages, with users criticizing the frenzy over Pelosi’s involvement and some reporting profit-taking after the stock’s rally.<stembedurl>https://stocktwits.com/WallStreetBetzBoss/message/601130338</stembedurl><stembedurl>https://stocktwits.com/HIGHTABLETRADES/message/601134687</stembedurl><stembedurl>https://stocktwits.com/Harvz90/message/601192109</stembedurl>A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.&nbsp;That caused a brief dip in the stock earlier on Thursday, although it rebounded later in the session.Tempus AI has a short interest of 5.5%, according to Koyfin data.Shares of the company have gained over 33% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.

Options Alert: Should Investors Jump on This Cathie Wood-Owned Life Sciences Specialist?

While proteomics firms Quantum-Si has made waves recently, QSI stock might not be the long-term play value investors are seeking.

Intellia Therapeutics, Inc. ($NTLA) shares plunged hard on Thursday after the small-cap, clinical-stage biotech reported results from mid-stage study results of its CRISPR-based gene-editing therapy codenamed NTLA-2002 in patients with hereditary angioedema (HAE).HAE is a rare genetic disorder that manifests as severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body. The condition could lead to potentially life-threatening swelling attacks.&nbsp;The disorder has no curative therapies but current preventive therapies have to be administered lifelong.&nbsp;Intellia said the results from the Phase 2 study showed NTLA-2002 has the potential to eliminate HAE attacks following a one-time infusion.&nbsp;Among the findings from the study are:<ul><li>Both dose levels tested (25 mg and 50 mg) reduced mean monthly attacks, with the latter dose resulting in a 77% reduction during weeks 1-16 and 81% reduction in weeks 5-16.</li><li>Eight of the 11 patients in the 50 mg arm were completely attack free following one-time infusion</li><li>Safety and tolerability profiles were encouraging.</li></ul>“We are highly encouraged by these results, which we believe sets NTLA-2002 apart from other prophylaxis treatments. What was previously an unimaginable potential to be free of chronic therapy is one step closer to becoming a reality for the HAE community,” said John Leonard, CEO of Intellia.The company said it has selected the 50 mg formulation for evaluation in the global Phase 3 study dubbed ‘HALEO.’ Screening for the study is currently ongoing, it said.HAE therapeutics market was at $4.1 billion in 2023 and is estimated to grow at 9.2% compounded annual growth rate between 2024 and 2032,<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gminsights.com/industry-analysis/hereditary-angioedema-therapeutics-market"> according</a> to Global Market Insights.The negative reaction could be due to the “buy-the-rumor, sell-the-news” phenomenon as the stock tacked on about 17%&nbsp;gains from a near-term (Oct. 10) low of $17.09.<figure class="image"><a href="https://stocktwits.com/symbol/NTLA"><img style="aspect-ratio:633/142;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/intellia_sentiment_b2935066a6.png" alt="intellia-sentiment.png" width="633" height="142"></a><figcaption>NTLA sentiment and message volume October 24, 2024, as of 11:05 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail trader sentiment was ‘extremely bearish’ (21/100), reversing from ‘bullish’ mood a day ago, with message volume spiking to ‘extremely high.’At 11:05 am ET, the stock was down 19.51% at $16.05, although off the day’s low of $15.52, which marked the lowest level in over four years.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ups-earnings-and-revenue-beat-estimates/cJ218XiR7Q">UPS Stock Soars Pre-Market, Keeps Retail Bullish As Q3 Beat Pleases Wall Street</a>For updates and corrections email newsroom@stocktwits.com

Intellia's mid-stage gene-editing therapy study results did not impress investors.

Intellia Stock Plunges To 4-Year Low Despite Promising Mid-Stage Study Results For Rare Genetic Disorder Therapy, Retail Sentiment Dips

Intellia stock tumbled to its lowest level in over four years as investors shrugged off what the company touted as promising results for its hereditary angioedema investigational gene-editing therapy.

Shares of Moderna plunged nearly 17% during the pre-market session after the company trimmed its full-year forecast. It cited low EU sales in 2024, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the U.S.Moderna now expects 2024 net product sales between $3.00 billion and $3.50 billion from its respiratory franchise compared to previous guidance of $4 billion.Following the announcement, retail sentiment dipped into ‘extremely bearish’ territory (16/100) souring further from yesterday’s ‘bearish’ reading.<figure class="image"><a href="https://stocktwits.com/symbol/MRNA"><img style="aspect-ratio:786/224;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_01_at_9_33_23_AM_44abb6c210.png" alt="Moderna sentiment meter as of 8:47 a.m. on August 01, 2024" width="786" height="224"></a><figcaption>Moderna sentiment meter as of 8:47 a.m. on August 01, 2024</figcaption></figure>On a positive note, the vaccine-maker reported an earnings loss of $3.33 during the second quarter versus an estimated loss of $3.39. Revenue came in at $241 million compared to a forecast of $132 million. Despite beating the analyst estimate, revenue declined 30% year-over-year (YoY) weighed down by decreased sales of the company's COVID-19 vaccine.Stéphane Bancel, Chief Executive Officer of Moderna stated that the firm has significantly lowered its operating costs during the second quarter. “We remain focused on execution for the 2024-25 COVID season and the launch of our RSV vaccine in the U.S.,” he said.Bancel stated the firm is involved in discussions with governments across Europe but some of them have pointed toward a tight budget restraining their capacity to buy more vaccines. The firm reportedly expects to see sales growth by 2025 and hit a breakeven position by 2026.Retail investors aren’t happy with the full-year guidance trim and the company’s efforts on the Covid vaccine given that its demand remains uncertain. One Stocktwits user expressed his ‘bearish’ view by stating that Moderna lowered its already lowered guidance, a sign it still has work to do in sufficiently diversifying its revenue streams.<figure class="image"><a href="https://stocktwits.com/JonOliNYC2020/message/581403885"><img style="aspect-ratio:794/160;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_01_at_9_34_35_AM_028dd1393e.png" alt="Stocktwits user JonOliNYC2020's post on Moderna stock " width="794" height="160"></a><figcaption>Stocktwits user JonOliNYC2020's post on Moderna stock&nbsp;</figcaption></figure>

Moderna now expects 2024 net product sales between $3.00 billion and $3.50 billion

Moderna Surpassed Q2 Earnings Estimates: Here’s Why Retail Sentiment Is ‘Extremely Bearish’ And The Stock Is Down 17%

While the vaccine-maker’s revenues beat estimates and its loss narrowed, management slashed its full-year sales forecast. Moreover, its struggles with EU sales and uncertainty over COVID vaccine demand remain key concerns for investors.

ARK Investment Management LLC - ARK Genomic Revolution ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$30.85
Prev Close	$31.17
Open	$31.06
Dividend Yield	N/A
50-Day Moving Average	$30.14
Beta	N/A
Avg. Volume	4.04M
PE Ratio	N/A

52-Week High	$34.07
52-Week Low	$17.51
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

ARKG
ARK Investment Management LLC - ARK Genomic Revolution ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ARKG News

ARKGARK Investment Management LLC - ARK Genomic Revolution ETF